Myocardial Infarction
Conditions
Keywords
Myocardial Infarction, Platelets, Blood Collection, Genomics
Brief summary
This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.
Interventions
None listed
Sponsors
NYU Langone Health
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
* Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms * Objective evidence of MI (either or both of the following): * Elevation of troponin to above the laboratory upper limit of normal (ULN) * ST segment elevation of ≥1mm on 2 contiguous ECG leads * Willing to provide informed consent and comply with all aspects of the protocol * Administration of aspirin at least 1 hour before cardiac catheterization * Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization * Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate
Exclusion criteria
* Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month) * Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma * Pregnancy * Thrombolytic therapy for STEMI (qualifying event) * Use of any of the following medications: * Platelet antagonists (except aspirin and thienopyridines) within 7 days * NSAIDs (e.g., ibuprofen, naproxen) within 3 days. * Thrombocytopenia (platelet count \<100,000) * Thrombocytosis (platelet count \>500,000) * Anemia (hemoglobin \<9 mg/dl) * Hemorrhagic diathesis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Examination of Platelet Activity Markers | 1 year | — |
| Examination of Markers of Cardiovascular Disease Risk | 1 year | This will include additional examination of known thrombosis, Inflammation, metabolic disease, and lipids/lipoprotein markers. |
| Cellular and molecular mechanism of myocardial infarction in women | 1 year | To further investigate this mechanism, recent advances in microRNA, RNA, DNA expression profiling, and plasma and serum collections will be used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Examination of non-coding and coding mRNA profiles in women with MI and matched controls | 4 years | Specific transcripts associated with platelet activation, plaque destabilization, and different cardiovascular diseases will be analyzed at the genetic level. |
Countries
United States
Contacts
CONTACTJeffrey Berger, MD
CONTACTHarmony R Reynolds, MD
PRINCIPAL_INVESTIGATORHarmony R Reynolds, MD
NYU Langone Medical Center
Outcome results
None listed